NASH
Akero Therapeutics’ shares plummet after phase 2b trial of NASH drug fails to improve cirrhosis
Anika Sharma
Akero Therapeutics, a leading contender in the nonalcoholic steatohepatitis (NASH) field, has encountered a setback as its FGF21 analog, efruxifermin ...
Inventiva and Kezar partner with Asian biotechs to advance NASH and lupus drugs
Anika Sharma
In a strategic move, Inventiva and Kezar Life Sciences have successfully secured buyers for the Asian rights to their lead ...
Madrigal’s NASH drug gets fast-track review from FDA, no panel needed
Anika Sharma
In the wake of a recent CEO transition, Madrigal Pharmaceuticals has disclosed that its nonalcoholic steatohepatitis (NASH) drug has been ...
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Anika Sharma
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
